Fund Manager Summary
The fund managers believe that Neuren Pharmaceuticals Ltd presents a compelling investment opportunity following its recent clinical trial successes, particularly with NNZ-2591. In their opinion, the phase 2 results for Pitt Hopkins syndrome demonstrate statistically significant improvements across all efficacy measures, marking a crucial de-risking event for the drug's commercialization. With NNZ-2591 now validated for two rare disease indications, this opens a multibillion-dollar market opportunity. The Endeavor team noted the importance of their recent meeting with Neuren management, which coincided with the trial results, indicating a catalyst-rich period ahead that could drive further share price gains. The positive momentum is reflected in a 13% rise in shares during May, suggesting strong investor interest.
Source: Trading View
Commentary From The Managers
Subscribe To Unlock
Date
Price
Summary
Unlock Recent Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Seneca Financial Solutions
31 July 2025
$17.29
Summary
- Neuren Pharmaceuticals (NEU) rose 23% during the month.
- Seneca Financial Solutions covered their investment thesis in detail on Livewire.
- At the current buy price, investors are acquiring Neuren's Daybue drug for rare diseases at a meaningful discount.
- Additionally, there is a free option on the second drug NNZ-2591, which is in phase 3 trials.
- The stock appears to be re-rating without significant news, aside from an ongoing share buyback.
- Seneca Financial Solutions believes Neuren is gaining investor attention and moving closer to fair value.
- The option value on NNZ-291 is expected to increase over time.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Updates are made available to members within 12 hours in accordance with the ThesisTracker Pro Service Level Agreement.
Please note: The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
Seneca Financial Solutions
31 July 2025
$17.29
- Neuren Pharmaceuticals (NEU) rose 23% during the month.
- Seneca Financial Solutions covered their investment thesis in detail on Livewire.
- At the current buy price, investors are acquiring Neuren's Daybue drug for rare diseases at a meaningful discount.
- Additionally, there is a free option on the second drug NNZ-2591, which is in phase 3 trials.
- The stock appears to be re-rating without significant news, aside from an ongoing share buyback.
- Seneca Financial Solutions believes Neuren is gaining investor attention and moving closer to fair value.
- The option value on NNZ-291 is expected to increase over time.
Summary
Milford Asset Management
31 May 2025
$13.57
- Neuren Pharmaceuticals rebounded by 19.0% following the finalisation of its Phase 3 trial design for Phelan-McDermid syndrome.
- The drug NNZ-2591 has the potential to serve as a multi-indication platform.
- It targets a range of rare genetic neurodevelopmental disorders.
- Milford Asset Management believes that as key regulatory milestones are achieved, the company’s full value will be increasingly recognised.
- New indications for the drug are being explored, enhancing its potential.
Summary
Seneca Financial Solutions
31 May 2025
$13.57
- Neuren Pharmaceuticals (NEU) rallied +19% during the month.
- Seneca Financial Solutions believes the current setup represents attractive asymmetric upside.
- The investment thesis is underpinned by the existing profitable drug Daybue for Rett Syndrome.
- Neuren has a healthy cash balance of $200 million with no debt.
- There is a free option on its second drug NNZ-2591, which is entering late-stage trials.
Summary
Endeavor Asset Management
31 Oct 2024
$12.35
- Endeavor Asset Management notes a recent 18.4% decline in the share price of Neuren Pharmaceuticals (NEU) due to an FDA update that did not meet investor expectations.
- Despite this setback, NEU is working on a resubmission to the FDA, providing further information about the endpoints for the primary efficacy assessment.
- NEU is engaged in a world-first pivotal clinical trial program for Phelan-McDermid syndrome (PMS).
- There are currently no approved medications for PMS, which significantly impacts the quality of life for those affected.
- Endeavor Asset Management continues to hold its position as it expects NEU to successfully navigate the FDA's next steps.
Summary
Endeavor Asset Management
31 May 2024
$21.64
- Neuren Pharmaceuticals Ltd. (NEU) continues to impress with strong clinical trial results for NNZ-2591.
- The Phase 2 results for Pitt Hopkins syndrome showed statistically significant improvements in all four efficacy measures.
- This marks a key de-risking event for the drug's pathway to sales.
- With effectiveness demonstrated for two rare disease indications, this opens a multibillion-dollar market opportunity.
- The Endeavor team met with Neuren management at the annual general meeting after the positive trial results.
- A catalyst-rich period lies ahead, expected to drive further share price gains.
- Neuren shares rose 13% in May.
Summary
Milford Asset Management
31 May 2024
$21.64
- Neuren Pharmaceuticals saw a performance increase of 12.7% following positive readout results for NNZ-2591 in treating Pitt-Hopkins syndrome.
- The results showed consistency, efficacy, and a benign safety profile that exceeded expectations.
- Milford Asset Management believes the company is still catalyst rich, with additional topline results for its drug treating Angelman syndrome anticipated within six weeks.
Summary
Oracle Advisory Group
31 Mar 2024
$21.51
- Oracle Advisory Group highlights that Neuren focuses on rare diseases in paediatrics.
- The first commercialized product is Trofinetide for Rett syndrome, the only approved treatment for the condition.
- Market forecasts suggest Trofinetide may capture 50% market share of all Rett syndrome patients in the US, viewed as conservative.
- Neuren has partnered with Acadia for global distribution, securing royalties and milestone payments from Trofinetide sales.
- This partnership enables a capital light business model generating significant cash flow post-approval.
- Cash generated is being utilized to fund the development of a second drug for other rare paediatric diseases.
- Development costs for new drugs are minimal, allowing for substantial excess cash available to shareholders.
Summary
Blackwattle Investment Partners
28 Feb 2024
$19.15
- Blackwattle Investment Partners continues to hold Neuren Pharmaceuticals Ltd (NEU) despite recent performance setbacks.
- NEU was the largest negative contributor, falling 19% in February due to a short seller report targeting Acadia Pharmaceuticals (ACAD), its US partner.
- There is skepticism among market participants regarding Neuren/Acadia’s early success in treating Rett Syndrome.
- Blackwattle disagrees with key elements of the short thesis and identifies multiple positive aspects of the company.
- The collaboration with ACAD is seen as beneficial for NEU.
- While DAYBUE is not a miracle cure, it enhances the quality of life for patients with manageable side effects.
- NEU is not just focused on DAYBUE; it possesses a promising drug pipeline that could make it a significant player in the pharmaceutical industry.
- Blackwattle maintains a significant position in NEU due to potential unrealized value and a favorable quality improvement trajectory.
Summary
Blackwattle Investment Partners
31 Jan 2024
$23.62
- Blackwattle Investment Partners notes Neuren Pharmaceuticals was a minor negative contributor in January.
- Neuren's stock price fell 5%, seen as a natural pause after a substantial 115% rise over the prior 3 months.
- This previous rise was attributed to strong revenue growth from DAYBUE, their approved drug for Rett Syndrome in the US.
- Positive Phase 2 trial results for NNZ-2591 further enhanced confidence in the company.
- The exciting Phase 2 results facilitate progress towards a Phase 3 trial for NNZ-2591.
- Blackwattle Investment Partners continues to retain a significant position due to multiple value accretive catalysts anticipated in 2024.
Summary
Spheria Asset Management
31 Dec 2023
$24.82
- Spheria Asset Management observes that Neuren Pharmaceuticals (NEU.ASX) share price increased by 61% in December.
- Despite this rise, Spheria Asset Management did not own shares in Neuren, resulting in a performance detractor.
- Neuren is a biopharmaceutical company focused on developing therapies for debilitating neurodevelopmental disorders in early childhood.
- One of their approved drugs, trofinetide (marketed as “Daybue”), is designed to treat Rett syndrome.
- The recent share price surge was driven by positive results from its Phase 2 trial.
Summary
Please note: The completeness, accuracy or current status of the investments referenced are not guaranteed.
ANALYST INSIGHT
Equity Research Analyst
"A compelling narrative is unfolding; Neuren Pharmaceuticals seems poised to capitalize on a multibillion-dollar opportunity with NNZ-2591. The recent trial results not only de-risk the pipeline but also hint at a promising trajectory for future share price gains."
Last Updated: 31 Jul 2025
Query The Data
Frequently Asked Questions
Who is investing in Neuren Pharmaceuticals Ltd (ASX:NEU)?
Fund managers including Endeavor Asset Management, Milford Asset Management, Spheria Asset Management, Blackwattle Investment Partners, Oracle Advisory Group and Seneca Financial Solutions have invested in Neuren Pharmaceuticals Ltd (ASX:NEU).
Why do fund managers invest in Neuren Pharmaceuticals Ltd?
Fund managers are investing in Neuren Pharmaceuticals Ltd due to its promising clinical trial results for NNZ-2591, particularly in treating rare diseases like Pitt Hopkins syndrome. The statistically significant improvements in efficacy measures represent a key de-risking milestone, unlocking potential access to a multibillion-dollar market. With strong management engagement and a pipeline rich in catalysts, fund managers anticipate further share price appreciation.
What happened to Neuren Pharmaceuticals Ltd (ASX:NEU)?
Fund managers are investing in Neuren Pharmaceuticals Ltd due to its promising drug pipeline, particularly the Daybue drug for rare diseases, which they believe is undervalued. Additionally, the ongoing Phase 3 trials for NNZ-2591 present a significant upside potential. Recent stock performance indicates a re-rating towards fair value, driven by increasing investor interest and an active share buyback program.